Design
Review
Authors
Loading...
These polymorphisms may heighten thrombotic risk; leaves open their value as therapeutic targets or risk stratifiers pending large-scale validation.
Key points are not available for this paper at this time.
Thomas J. Kunicki (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: